PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial



Status:Completed
Conditions:Cervical Cancer, Cardiology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:12/6/2018
Start Date:June 16, 2015
End Date:January 4, 2018

Use our guide to learn which trials are right for you!

To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the
regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal
triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure
will be percent change in central subfield thickness as measured by OCT at 8 weeks.
Participants will continue in the study for 24 weeks in order to evaluate relative effects of
the 3 treatment strategies on the duration of treatment effects, requirement for additional
injections, and adverse effects.

Note: The planned sample size for the POINT Trial was 267 subjects. On 17 July 2017, with 192
subjects enrolled, the Data and Safety Monitoring Committee (DSMC) reviewed the planned
interim analysis and recommended that the goals of the trial could be accomplished by
completing follow-up of enrolled subjects without the recruitment of additional subjects. Per
the DSMC recommendations, recruitment was suspended and follow-up of enrolled subjects was
completed according to the protocol.

Macular edema is the most common structural complication and leading cause of visual loss in
patients with uveitis. Regional injections of corticosteroids are the most frequently used
treatments specifically for uveitic macular edema but there is a lack of high quality
evidence to guide choice of drug (e.g., triamcinolone acetonide, dexamethasone) and route of
administration (e.g. periocular, intravitreal). The question of how to approach regional
treatment of uveitic macular edema is a key question for ophthalmologists treating these
patients. The Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT)
Trial is a randomized trial designed to compare the relative efficacy of three regional
corticosteroids commonly utilized for the initial regional treatment of uveitic macular
edema, periocular triamcinolone (Kenalog® , Bristol-Myers Squibb Company, Princeton, NJ),
intravitreal triamcinolone (Triesence™, Alcon Pharmaceuticals, Fort Worth, TX), and the
intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine CA) will be conducted by the
MUST Research Group clinical centers throughout the U.S. and one each in Australia and the
UK. After signing informed consent and undergoing eligibility evaluation, eligible patients
will be randomized to one of the three study treatments to be administered at the first study
visit. Randomization is by participant, if both eyes meet eligibility requirements then both
eyes receive assigned treatment. The design outcome is the percent change in central subfield
macular thickness on OCT from baseline to the 8 week visit. After assessment of the primary
outcome at 8 weeks, second injections and best medical judgment will be used if macular edema
has not improved as follows:

Eye(s) meeting trial eligibility criteria receive initial injection of assigned treatment at
P01 visit.

Second injection of assigned treatment permitted at 8 week visit for periocular triamcinolone
and intravitreal triamcinolone and at 12 week visit for intravitreal dexamethasone if

- Eye does not meet the improvement definition (a 20% decrease in central subfield
thickness of the macula) or

- Eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central
subfield or

- ME is worse after initial improvement

And the following repeat injection criterion are met:

• IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;

Eyes demonstrating no improvement or worsening of ME as measured by the central submacular
thickness on OCT (at week 12 for periocular and intravitreal triamcinolone arms and at week
20 for intravitreal dexamethasone arm) are considered primary treatment non-responders.

Inclusion Criteria:

Eye level inclusion criteria - at least one eye must meet all of the following conditions:

- Non-infectious anterior, intermediate, posterior or panuveitis; either active or
inactive uveitis is acceptable;

- Macular edema (ME) defined as the presence of central subfield macular thickness
greater than the normal range for the OCT machine being used, regardless of the
presence of cysts, as assessed by study ophthalmologist;

- Best corrected visual acuity (BCVA) 5/200 or better;

- Baseline intraocular pressure > 5 mm Hg and ≤ 21 mm Hg (current use of 3 or fewer
intraocular pressure-lowering medications and/or prior glaucoma surgery are
acceptable);

- Baseline fluorescein angiogram that is gradable for leakage in the central subfield

- Pupillary dilation sufficient to allow OCT testing.

Exclusion Criteria:

Patient level exclusion criteria:

-History of infectious uveitis, or of scleritis, keratitis, or infectious endophthalmitis
in either eye;

History of central serous retinopathy in either eye;

- For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy
test; unwilling to practice an adequate birth control method (abstinence, combination
barrier and spermicide, or hormonal) for duration of trial;

- Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;

- Oral prednisone dose > 10 mg per day (or of an alternative corticosteroid at a dose
higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10
mg per day that has not been stable for at least 4 weeks(note that if patient is off
of oral prednisone at baseline (P01 visit), dose stability requirement for past 4
weeks does not apply);

- Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks;

- Known allergy or hypersensitivity to any component of the study drugs;

Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot
have any of the following conditions:

- History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9
or any notching of optic nerve to the rim);

- Media opacity causing inability to assess fundus or perform OCT;

- Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of
study ophthalmologist may be significant enough to limit improvement of ME (i.e.,
causing substantial wrinkling of the retinal surface)81;

- Torn or ruptured posterior lens capsule;

- Presence of silicone oil;

- Periocular or intravitreal corticosteroid injection in past 8 weeks;

- Injection of dexamethasone intravitreal implant in past 12 weeks;

- Placement of fluocinolone acetonide implant (Retisert) in past 3 years;
We found this trial at
25
sites
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Steven Yeh, MD
Phone: 404-778-2421
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Jennifer Thorne, MD
Phone: 410-502-6782
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Phone: 319-356-8161
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Phone: 206-543-7250
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Peter R Pavan, MD
Phone: 813-974-7739
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Ann Arbor, Michigan 48105
Principal Investigator: Susan G Elner, MD
Phone: 734-936-0138
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bethesda, Maryland 20892
Principal Investigator: Hatice N Sen, MD
Phone: 301-435-4529
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Boston, Massachusetts 02114
Phone: 617-314-2703
?
mi
from
Boston, MA
Click here to add this to my saved trials
243 Charles St
Boston, Massachusetts 02114
(617) 523-7900
Phone: 617-573-3002
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Pauline Merrill
Phone: 312-563-4032
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Durham, North Carolina 27710
Principal Investigator: Glenn J Jaffe, MD
?
mi
from
Durham, NC
Click here to add this to my saved trials
East Melbourne,
Principal Investigator: Richard Stawell
Phone: 61 3 9929 8076
?
mi
from
East Melbourne,
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Rosa Y Kim, MD
Phone: 713-524-3434
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California
Principal Investigator: Gary Holland, MD
Phone: 310-794-5602
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Janet Davis, MD
Phone: 305-326-6348
?
mi
from
Miami, FL
Click here to add this to my saved trials
New York, New York
Principal Investigator: Paul Latkany, MD
Phone: 212-687-0265
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: John H Kempen, MD, PhD
Phone: 215-662-8691
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Albert Vitale, MD
Phone: 801-581-6265
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Nisha Acharya, MD
Phone: 415-476-4494
?
mi
from
San Francisco, CA
Click here to add this to my saved trials